FS Development II said its registration statement on Form S-4 outlining its proposed merger with Pardes Biosciences has been declared effective by the SEC. The SPAc’s stockholders are set to vote on the deal Dec. 23.
As announced in June, the combined company is expected to receive gross proceeds of approximately $276 million.
Pardes’ oral antiviral drug candidate is designed to inhibit an essential viral protein, the main protease of SARS-CoV-2, the virus causing COVID-19.
If the deal is approved, Pardes common stock is expected to list on the Nasdaq under PRDS. Read more.
